EP3741218A1 - Lactobacillus salivarus strain and its use in the prevention and treatment of post-weaning diarrhea in piglets - Google Patents
Lactobacillus salivarus strain and its use in the prevention and treatment of post-weaning diarrhea in piglets Download PDFInfo
- Publication number
- EP3741218A1 EP3741218A1 EP19382407.5A EP19382407A EP3741218A1 EP 3741218 A1 EP3741218 A1 EP 3741218A1 EP 19382407 A EP19382407 A EP 19382407A EP 3741218 A1 EP3741218 A1 EP 3741218A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- strain
- salivarius
- composition
- cfu
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186869 Lactobacillus salivarius Species 0.000 title claims abstract description 84
- 238000011282 treatment Methods 0.000 title claims abstract description 32
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 26
- 230000002265 prevention Effects 0.000 title claims abstract description 22
- 241001465754 Metazoa Species 0.000 claims abstract description 43
- 239000006041 probiotic Substances 0.000 claims abstract description 27
- 235000018291 probiotics Nutrition 0.000 claims abstract description 27
- 230000000529 probiotic effect Effects 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 67
- 230000000694 effects Effects 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 239000005913 Maltodextrin Substances 0.000 claims description 8
- 229920002774 Maltodextrin Polymers 0.000 claims description 8
- 229940035034 maltodextrin Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 description 29
- 241000282898 Sus scrofa Species 0.000 description 20
- 241000282887 Suidae Species 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- 244000005700 microbiome Species 0.000 description 12
- 210000000936 intestine Anatomy 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 229920001542 oligosaccharide Polymers 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 244000052769 pathogen Species 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241000186660 Lactobacillus Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000001332 colony forming effect Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000013406 prebiotics Nutrition 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 235000021050 feed intake Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000005024 intraepithelial lymphocyte Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000615866 Antho Species 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000008723 osmotic stress Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 108010062877 Bacteriocins Proteins 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 108010078777 Colistin Proteins 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- -1 citric Chemical compound 0.000 description 2
- 229960003346 colistin Drugs 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009313 farming Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 2
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000510930 Brachyspira pilosicoli Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000946390 Catenibacterium Species 0.000 description 1
- 108050004290 Cecropin Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 241001657523 Coriobacteriaceae Species 0.000 description 1
- 241000031711 Cytophagaceae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000609971 Erysipelotrichaceae Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241001568673 Geobacteraceae Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 241001580017 Jana Species 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000019735 Meat-and-bone meal Nutrition 0.000 description 1
- 241000604449 Megasphaera Species 0.000 description 1
- 101100459301 Mus musculus Myl4 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000031708 Saprospiraceae Species 0.000 description 1
- 241000192023 Sarcina Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241001657520 Slackia Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194018 Streptococcaceae Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 241000203626 Thermomonosporaceae Species 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 241001425419 Turicibacter Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004674 formic acids Chemical class 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 108010078656 plectasin Proteins 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009211 stress pathway Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 231100000164 trypan blue assay Toxicity 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/181—Salivarius
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Definitions
- the invention relates to the field of probiotic strains, in particular to a new probiotic strain of Lactobacillus salivarius, to compositions comprising said probiotic strain, and its use for the prevention and/or treatment of diseases, in particular of post-weaning diarrhea in pigs.
- Diarrhea (or scour) in piglets is one of the most common problems in pig farming affecting hundreds of millions of piglets born globally each year. It can result in reduced weight gain, high cost of treatment and frequent mortality. Piglets set back in health at an early age, tending to remain at a weight and performance disadvantage in later life. Therefore, diarrhea not only has a detrimental impact on piglet health, but on farm profitability.
- Piglet diarrhea caused by Escherichia coli ( E. coli ) strains is common within the first weeks after weaning, and also in the first weeks of life. Diarrhea in pre-weaned piglets (suckling pigs) can be fatal since piglets can become quickly dehydrated and mortality rates are high.
- Weaning is a critical period in a piglet's life. It must cope with separation from the sow, the transition from highly digestible milk to a less digestible and more complex solid feed, a new environment, movement and separation from littermates, and exposure to unfamiliar pigs. These stress factors can lead to reduced feed intake and reduced piglet growth. Additionally, the newly-weaned pigs' immune and digestive systems are still maturing, making the piglet more susceptible to antigenic challenges (nutritional or microbial), which can lead to inflammatory responses. Inflammation induces a negative impact on the digestive and absorptive capabilities of the gut, and overall gut health creating an opportunity for an animal to become more susceptible to pathogens.
- PWD post-weaning diarrhea
- Feed intake is usually reduced initially after weaning and the pig may develop anorexia of variable duration and extent between farms, depending on livestock management and the nature of the feed.
- Underfeeding during weaning reduces growth performance of pigs and contributes to intestinal inflammation and adversely affects villous height and crypt depth.
- This morphological disruption of the intestinal mucosa promotes the creation of an ideal environment for the multiplication of bacteria such as E. coli and allows toxins and bacteria to cross the epithelium as a result of this inflammation.
- Antibiotics such as colistin
- colistin are widely used for the control of PWD in pigs.
- this antibiotic is considered as one of the last therapeutic options for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Since food producing animals, and in particular pigs, have been singled out as the most potential reservoirs for spread and amplification of colistin resistance, scientists and regulatory agencies have recommended reducing the use of said antibiotic in animal production.
- feed supplements such as zinc oxide, organic acids (such as citric, fumaric, lactic, propionic, benzoic and formic acids), prebiotics (such as inulin, oligosaccharides, e.g. galactooligosaccharides and fructooligosaccharides), probiotics (such as L. rhamnosus and L. acidophilus ), dehydrated porcine plasma, antimicrobial peptides (such as lactoferrin, cecropin, defensing, plectasin and bacteriocins), specific egg yolk antibodies, bacteriophages and probiotics.
- prebiotics such as inulin, oligosaccharides, e.g. galactooligosaccharides and fructooligosaccharides
- probiotics such as L. rhamnosus and L. acidophilus
- dehydrated porcine plasma such as lactoferrin, cecropin, defensing, plectasin and bacterioc
- Probiotics are defined by the World Health Organization as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.
- Probiotic products may be formulated as capsules, tablets, powders (which are regulated as a dietary supplement), and a feed or food ingredient (e.g., yogurts, kefirs), or as a drug.
- Probiotics may exert a wide range of beneficial effects, such as balancing the host gut microbiota and interacting with the innate and adaptive immune system, which may promote resistance against pathogens.
- probiotics are Lactobacillus and Bifidobacterium species, followed by the genera Streptococcus, Enterococcus, Propionibacterium, Bacillus, and Escherichia coli.
- yeast species are used as probiotics, for example, Saccharomyces boulardii and Saccharomyces cerevisiae are frequently used to treat gastrointestinal disorders.
- Lactobacillus salivarius is a species commonly isolated from the gastrointestinal tract of humans and animals with potential probiotic properties. Results of previous studies have shown a considerable functional diversity existing both in the chromosome and in the plasmids of different strains. A variety of bacteriocins with different spectra of activity against pathogens are coded in these plasmids [ Harris et al., Microb Genom., 2017, 3, e000115 ]. The production of these antibacterial proteins is widely distributed within the strains of this species, providing them with the ability to modulate the intestinal microbiota and reduce the impact of pathogens, such as Listeria monocytogenes [ O 'Shea et al., Gut Microbes, 2012, 3(5), 468-473 ].
- pathogens such as Listeria monocytogenes [ O 'Shea et al., Gut Microbes, 2012, 3(5), 468-473 ].
- strains of L. salivarius have shown activity against Streptococcus mutans, which is involved in the production of caries [ Sa ⁇ udo et al., Arch Oral Biol., 2017, 84, 58-63 ], and against Aggregatibacter actinomycetemcomitans, which is involved in periodontal disease [ Sajedinejad et al., Probiotics Antimicrob Proteins, 2018, 10, 485-495 ].
- strains of L. salivarius present antimicrobial activity against Gardnerella vaginalis and Candida albicans, which are implicated in vulvovaginitis [ Kang et al., Probiotics Antimicrob Proteins, 2018, 10, 343-349 ].
- salivarius strains have shown activity against Staphylococcus aureus [ Heikkilä and Saris, J Appl Microbiol., 2003, 95, 471-478 ; Kang et al., Pathog Dis., 2017, 75(2). doi:10.1093/femspd/ftx009 ], S. epidermidis [ Arroyo et al., Clin Infect Dis., 2010, 50, 1551-1558 ] and against enterobacteria [ Abhisingha et al., Probiotics Antimicrob Proteins, 2018, 10, 218-227 ].
- L. salivarius has been effective in the control of Salmonella, Brachyspira pilosicoli and Campylobacter jejuni in poultry farms [ Mappley et al., Appl Environ Microbiol., 2011, 77, 5402-5411 ; Ghareeb et al., Poult Sci., 2012, 91, 1825-1832 ; Yamakazi et al., Br Poult Sci., 2012, 53, 183-189 ]. In pigs, the administration of L.
- the inventors have isolated and characterized a probiotic strain of Lactobacillus salivarius (PS21603) isolated from the intestine of a wild boar, which has surprisingly been found to reduce the fecal E. coli concentration, to be useful for the prevention and/or treatment of diarrhea in a mammal, in particular post-weaning diarrhea in piglets.
- PS21603 Lactobacillus salivarius
- the Lactobacillus salivarius strain PS21603 of the invention has a great inhibitory activity of Escherichia coli, said Lactobacillus salivarius PS21603 strain has not shown any resistance to antibiotics, and animals treated with said strain have shown improved intestinal morphology (ratio of villous height to crypt depth and length of the small and large intestine). Therefore, the Lactobacillus salivarius strain PS21603 of the invention has shown a high potential for the treatment and/or prevention of diarrhea in a mammal, in particular PWD in pigs.
- the Lactobacillus salivarius PS21603 strain has been deposited at the Colecissus Tel ⁇ ola de Cultivos Tipo (CECT) and has been given accession number CECT 9673.
- the present invention is directed to a strain of Lactobacillus salivarius PS21603 or a variant thereof having at least 95% identity with this strain, wherein the variant strains are obtained by using the deposited strain as starter material, and wherein the variant strains retain or further improve the activity of the strain Lactobacillus salivarius PS21603.
- the strain has at least 97% identity with the strain of Lactobacillus salivarius PS21603.
- the invention also relates to a composition comprising the strain as defined above.
- the invention also relates to the strain or composition as defined above for use as a probiotic or for use as a prevention and/or therapeutic agent.
- the invention is directed to the strain or the composition as defined above, for use in the prevention and/or treatment of diarrhea in a mammal, in particular for the treatment and/or prevention of post-weaning diarrhea (PWD) in pigs.
- PWD post-weaning diarrhea
- the invention is directed to the strain or the composition as defined above, for use in improving performance of a mammal animal.
- the term "probiotic” means a microorganism that exerts beneficial effects on the health of the host. It can be a live microbial fed supplement or medicament that beneficially affects the host by improving its microbial balance, a microbial preparation that contains live or dead bacteria, or a combination of both.
- Hosts suitable in the context of the invention includes any mammal, such as pigs, horses, cows, goats, ewes, dogs, cats, rats, mice and primates, such as human beings; more preferably pigs.
- pig or “swine” includes domestic pigs and wild boars of any age, preferably piglets and weaners, both males and females.
- piglets refers to young pigs, such as from birth until weaning, which in pig farming generally takes place at the age of 2-4 weeks; and “weaners” refers to pigs from weaning until the age of about 10 weeks.
- the strain of Lactobacillus salivarius according to the invention is referred to as Lactobacillus salivarius PS21603 or L. salivarius PS21603.
- the strain L. salivarius PS21603 has been deposited by Probisearch SLU, Calle Santiago Grisol ⁇ a 2, Tres Cantos, Spain in accordance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure at the Colecissus Espa ⁇ ola de Cultivos Tipo (CECT) on 5 June 2018 and has been given Accession Number CECT 9673.
- strain is well-known in the field and means a genetic variant or subtype of a microorganism.
- a "variant” or “mutant” of a strain refer to any naturally-occurring or specifically developed strain obtained from the reference strain L. salivarius PS21603, mainly by mutation, that maintains or enhances the properties of the reference strain.
- the invention relates to variants of the reference strain in which one or more of the following properties associated to the L. salivarius PS21603 strain is preserved or enhanced:
- the reference to that the variant strain maintains the properties of the reference strain L. salivarius PS21603 means that, while not showing an activity of 100% of the activity of the reference strain L. salivarius PS21603 from which it derives, the property is substantially preserved so that the variant shows at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, at least 90%, at least 80%, at least 70%, at least 60%, at least 50% of the activity of the L. salivarius PS21603 strain from which it derives.
- the present invention also relates to strains of L. salivarius having at least 95 % identity with the 16S rRNA sequence of the L. salivarius PS21603 strain, which is described in the examples [reference Stackebrandt & Goebel, 1994: "Taxonomic Note: A Place for DNA-DNA Reassociation and 16s rRNA Sequence Analysis in the Present Species Definition in Bacteriology" Int. J. Syst. Bacteriol. 44:846-849].
- the strain according to the present invention has at least 97 % identity with the 16S rRNA sequence of the L. salivarius PS21603 strain, more preferably at least 98% identity, more preferably at least 99% identity. In another preferred embodiment, the strain according to the present invention has 100% identity with the 16S rRNA sequence of the L. salivarius PS21603 strain, i.e. the strain according to the present invention is the Lactobacillus salivarius PS21603 strain.
- strains of the invention as demonstrated in the examples, have sufficient resistance to the conditions of the acidic microenvironment of the gastrointestinal tract so that said strains may survive passage through the gastrointestinal tract.
- the strains have also shown good resistance to osmotic stress, which allows them to withstand lyophilization-rehydration processes used in industrial production of probiotics.
- the strain of the present invention may be alive or inactivated.
- Alive microorganisms produce a complete array of antigens, reproduce to increase the number of such organisms in the intestinal environment to better stimulate an immune response.
- the strain of the invention is alive.
- the term "inactivated” refers to a dead or inactivated cell of a microorganism which is no longer capable to form a single colony on a plate having medium specific for said microorganism, and it also encompasses lysates, fractions or extracts of the microorganism.
- the inactivation of a cell refers to a process of transforming a cell from viable to non-viable.
- the terms "viable”, “alive” or “viability”, as used herein, refer to the ability of a cell to maintain itself or recover its potentialities and survive until they are able to divide. Thus, a cell that is viable or alive indicates that the cell is able to survive and divide; conversely, a cell that is non-viable indicates that the cell is not able to survive and divide. It will be appreciated that non-viable cells include dead cells.
- Viability can be determined by a number of assays that are conventional in the art. These include cytolysis or membrane leakage assays, such as the lactate dehydrogenase assay, the propidium iodide assay, the trypan blue assay and the 7-aminoactinomycin D assay, as well as genomic and proteomic assays that test the activation of stress pathways using DNA microarrays and protein chips. Viability can also be determined by checking the absence of cells after their culture in an appropriate culture medium.
- the present invention relates to a composition
- a composition comprising the L. salivarius PS21603 strain of the invention, or variant thereof.
- compositions of the invention comprises the L. salivarius PS21603 strain of the invention or variant thereof and a physiologically acceptable carrier or excipient and/or further ingredients as described further below.
- the L. salivarius strain according to the invention is present in freeze-dried form.
- composition as used in the present invention relates to any composition of matter comprising the strain of the invention, i.e. L. salivarius PS21603 strain or variant thereof.
- the composition of the invention comprises the L. salivarius PS21603 strain or variant thereof and a veterinary or pharmaceutically acceptable excipients.
- These compositions can also be named as “veterinary composition”, “veterinary product”, “pharmaceutical composition” or “pharmaceutical product”.
- veterinary and “pharmaceutical” refer to the same type of product or ingredient but the first one being intended for animal use and the second one being intended for human use.
- veterinary composition or "veterinary product” are used herein interchangeably and refer to a formulation which has been adapted to administer a predetermined dose of one or several therapeutically useful agents, i.e. the strains of the invention, to a mammal animal, preferably pigs, in which a direct or indirect therapeutic effect of the composition is sought out.
- the veterinary composition of the invention contains a therapeutically effective amount of the Lactobacillus salivarius PS21603 strain of the invention or a variant thereof, which is understood herein as an amount capable of providing a therapeutic effect, and which can be determined by the person skilled in the art by commonly used means.
- the expressions "pharmaceutical composition” or “pharmaceutical product” are used herein interchangeably and refer to a formulation which has been adapted to administer a predetermined dose of one or several therapeutically useful agents to a mammal, preferably a piglet, in which a direct or indirect therapeutic effect of the composition is sought out.
- the pharmaceutical composition of the invention contains a therapeutically effective amount of the Lactobacillus salivarius PS21603 strain of the invention or a variant thereof, which is understood herein as an amount capable of providing a therapeutic effect, and which can be determined by the person skilled in the art by commonly used means.
- veterinary acceptable excipient and “pharmaceutical acceptable excipient” refer to a diluent or carrier with which the active ingredient, i.e. the strains of the invention, is administered.
- Acceptable excipients for therapeutic use are well known in the veterinary and pharmaceutical art, and are described, for example, in Remington: The Science and Practice of Pharmacy, Lippincott Williams and Wilkins (22nd Ed., 2012 ). The choice of veterinary and pharmaceutical excipient can be selected with regard to the intended route of administration and standard pharmaceutical and veterinary practice.
- such pharmaceutical and veterinary excipients include, but are not limited to, water, glucose, lactose, sucrose, mannitol, maltodextrin, (resistant) starch, cellulose or cellulose derivatives, e.g. methylcellulose, magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate and the like; preferably maltodextrin.
- Water or aqueous solutions of saline solution and aqueous dextrose and glycerol solutions are preferably used as excipients.
- compositions of the invention may comprise as - or in addition to - the excipients mentioned above any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilizing agent(s).
- Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical and veterinary compositions.
- preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid.
- Antioxidants and suspending agents may also be used. There may be different composition/formulation requirements depending on the different delivery systems.
- composition of the invention comprises maltodextrin as the veterinary or pharmaceutically acceptable excipient.
- the strain of the invention is present in a foodstuff.
- These compositions can also be named as terms “feed product”, “feed composition”, “food product” or “food composition”. These compositions relate to a feed or food that beneficially affects one or more functions of the body, so as to provide better health and wellness. Accordingly, such a feed or food product may be intended for the prevention and/or treatment of a disease or a disease causing factor. Therefore, these compositions can also be named as functional feed or food for particular nutritional purposes, or veterinary feed.
- feed and “food” and refer to a foodstuff but the first one being intended for animal use and the second one being intended for human use.
- feed refers to a commercial feed which is formulated according to the specific requirements of the target animal.
- Non-limiting examples of suitable foodstuffs which can be used in the present invention are animal feed, including feed premix, final feed product, pellets, cereals (such as corn, oats and barley), fermented cereal based products, other cereal based powders, soybean, copra, straw, grass, sugar beet waste, fish meal, meat and bone meal, seeds, bread, cakes, semi- or synthetic diet formulations, infant formulae, clinical nutrition formulae, flours.
- the foodstuff is an animal feed, such as pig feed.
- the effective amount of colony forming units (CFU) for each strain in the composition of the invention will be determined by the skilled person and will depend upon the final formulation and the times per day it will be administered.
- the strain of the invention is present in the compositions of the invention in an amount that provides about 10 5 CFU/day to about 10 11 CFU/day, preferably in an amount from about 10 6 CFU/day to about 10 10 CFU/day, more preferably in an amount from about 10 7 CFU/day to about 10 9 CFU/day.
- CFU refers to "Colony Forming Units". Quantification of bacteria in a given sample is routinely achieved by counting the total number of colony-forming units (CFUs) grown on an agar plate from serial dilutions, expressed as CFU per gram or mL of the original sample. This yields an estimate of the number of cells present based on a skilled interpretation of the number of colonies on a plate.
- CFUs colony-forming units
- a particularly preferred composition of the invention comprises the Lactobacillus salivarius PS21603 strain of the invention and maltodextrin.
- the composition comprises the Lactobacillus salivarius PS21603 strain of the invention and maltodextrin, wherein the amount of the Lactobacillus salivarius PS21603 strain of the invention is from 10 6 CFU to 10 8 CFU per gram (g) of composition.
- compositions of the invention comprises the Lactobacillus salivarius PS21603 strain of the invention, maltodextrin and an animal feed, such as pig feed.
- said compositions of the invention comprise from about 10 5 CFU/kg to about 10 11 CFU/kg, preferably from about 10 6 CFU/kg to about 10 10 CFU/kg, more preferably in from about 10 7 CFU/kg to about 10 9 CFU/kg, wherein the amounts are expressed as CFU of the strains of the invention per kg of feed.
- composition according to the invention may comprise further probiotics, apart from the L. salivarius PS21603 strain of the invention or a variant thereof as described above.
- Probiotics have beneficial effects on the immune system, hence the combination with probiotics will have a superior effect on immune system.
- the further probiotics are selected from the group consisting of Lactobacillus and Bifidobacterium.
- composition of the present invention may further contain prebiotics.
- Prebiotics may support the growth of probiotics before they are rendered non-replicating.
- Prebiotic means non-digestible food substances that promote the growth of health beneficial microorganisms and/or probiotics in the intestines. They are not broken down in the stomach and/or upper intestine or absorbed in the GI tract of the person ingesting them, but they are fermented by the gastrointestinal microbiota and/or by probiotics.
- they may be selected from the group consisting of oligosaccharides, optionally containing fructose, galactose, mannose; dietary fibers, in particular soluble fibers, soy fibers; inulin; or mixtures thereof.
- Preferred prebiotics are fructo-oligosaccharides, galactooligosaccharides, isomalto-oligosaccharides, xylo-oligosaccharides, arabino-xylo oligosaccharides, mannan-oligosaccharides, oligosaccharides of soy, glycosylsucrose, lactosucrose, lactulose, palatinose-oligosaccharides, malto-oligosaccharides, gums and/or hydrolysates thereof, pectins and/or hydrolysates thereof.
- the strains and compositions of the invention are safe and have an important beneficial effect.
- the strain of the invention prevented scours, increased animal weight, reduced fecal E. coli concentration, increased the length of the small and large intestine, and improved the ratio of villous height to crypt depth.
- the present invention relates to a strain or a composition as previously defined for use as a probiotic, as well as a prevention and/or therapeutic agent.
- the invention relates to a strain or a composition as previously defined, for use in the prevention and/or treatment of diarrhea in a mammal, preferably in a pig,
- the invention relates to a strain or a composition as previously defined, for use in the prevention and/or treatment of post-weaning diarrhea in a mammal, preferably in a pig.
- the strain is for use in the prevention and/or treatment by diarrhea caused by an E. coli infection.
- treat refers to reducing the potential for a certain disease or disorder, reducing the occurrence of a certain disease or disorder, and/or a reduction in the severity of a certain disease or disorder, preferably, to an extent that the subject no longer suffers discomfort and/or altered function due to it. It also refers to mitigating or decreasing at least one clinical symptom and/or inhibition or delay in the progression of the condition and/or prevention or delay of the onset of a disease or illness. It also means prolonging survival as compared to expected survival if not receiving the treatment.
- prevention refers to avoiding the appearance of a certain disease or disorder.
- the prevention can be complete (e.g. the total absence of a disease).
- the prevention can also be partial, such that for example the occurrence of a disease in a subject is less than that which would have occurred without the administration of the combination or composition of the present invention.
- Prevention also refers to reduced susceptibility to a clinical condition.
- the prevention also includes reducing the risk of suffering the disease.
- the strain and compositions of the invention also improve performance of an animal.
- performance refers to the productivity of an animal, such as a pig, measured by one or more of the following parameters: scours, mortality, number of animals born, number of animals born alive, litter birth weight, and immune system function.
- An improved performance refers to an improvement in at least one of the previously listed parameters.
- a further aspect the invention relates to a strain or a composition as previously defined for use in improving performance of a mammal animal, preferably a pig.
- the strains and composition for use in the present invention described above are preferably administered enterically, more preferably orally.
- the strain and composition for use according to the invention may be administered in a single daily dose or multiple doses per day, such as at least 2 doses per day, at least 3 doses per day, at least 4 doses per day.
- the strain and composition according to the invention are administered 1, 2 or 3 doses per day.
- the person skilled in the art will be able to adjust the therapeutically effective dose and/or the prophylactic effective dose appropriately. The precise dose depends on a number of factors such as the mammal's health and weight.
- the strain and composition of the invention are administered in an amount that provides a dose of the strain of 10 5 CFU/day to about 10 11 CFU/day, preferably in an amount from about 10 6 CFU/day to about 10 10 CFU/day, more preferably in an amount from about 10 7 CFU/day to about 10 9 CFU/day to the mammal receiving said strain or composition.
- the strain or composition of the invention is for use in a pig.
- the pig is a piglet or a weaner, even more preferably a weaner.
- the strain and composition of the invention is administered for about 2 to about 6 weeks, more preferably for about 3 to about 5 weeks, still more preferably for about 4 weeks (or about 1 month).
- the strain and composition of the invention is administered during the weaning period, more preferably for about 2 to about 6 weeks after weaning, even more preferably for about 3 to about 5 weeks after weaning, still more preferably about 4 weeks after weaning (or about 1 month after weaning).
- Lactobacillus salivarius PS21603 was isolated from the intestine of a wild boar. After the necropsy of the animal, gut content was recovered, diluted and plated in MRS (supplemented with cysteine (MRScys) medium. The incubation was done in anaerobic conditions, at 37°C for 48h.
- MRS supplied with cysteine
- the strain was identified at the species level as Lactobacillus salivarius by PCR amplification of a section of a 16S rRNA gene variable region using primers plb16 (5'-AGAGTTTGATCCTGGCTCAG-3', SEQ ID NO: 1) and mlb16 (5'-GGCTGCTGGCACGTAGTTAG-3', SEQ ID NO: 2) [ Kullen et al., Journal of Applied Microbiology, 2000, 89, 511-518 ].
- PCR conditions were as follows: 96 °C for 30 s, 50 °C for 30 s and 72 °C for 45 s (35 cycles) and a final extension at 72 °C for 4 min.
- Amplified fragments were purified using the NucleoSpin Extract II (Macherey-Nagel Gmb; Düren, Germany) and sequenced using the primers cited above on an ABI 377A automated sequencer (Applied Biosystems, Foster City, USA). The sequences were compared with those deposited in the EMBL database using BLAST algorithm (http://www.ncbi.nlm.nih.gov/BLAST)
- the fragment sequenced from L. salivarius PS2160316S rRNA gene has SEQ ID NO:3, which is reproduced below.
- the identification was confirmed by Matrix Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) mass spectrometry using a Vitek-MSTM instrument (BioMérieux, Marcy l'Etoile, France) in the facilities of Probisearch (Tres Cantos, Spain). Briefly, a portion of a bacterial colony ( ⁇ 1 uL) was directly spotted onto a MALDI sample plate. Then, it was overlaid with 1 ( ⁇ L of a saturated solution of ⁇ -cyano-4-hydroxycinnamic acid in acetonitrile (28%), and allowed to dry at room temperature. A mean spectrum was constructed with at least 50 m/z spectra profiles and used for the identification by comparison with the spectra contained in the Myla database (Biomerieux). Identification was defined as a 99% match to the species-specific m/z values in the database.
- MALDI-TOF Matrix Assisted Laser Desorption Ionization-Time of Flight
- the strain could be differentiated from other L. salivarius strains of our own collection by genotyping by randomly amplified polymorphic DNA (RAPD), pulsed-field gel electrophoresis (PFGE) analyses and the complete genome sequence.
- RAPD randomly amplified polymorphic DNA
- PFGE pulsed-field gel electrophoresis
- the MIC of the 8 antibiotics included in this study was determined on L. salivarius PS21603 cultures grown overnight in lactic acid bacteria susceptibility test medium (LSM) [ Klare et al., Journal of Antimicrobial Chemotherapy, 2005, 59, 900-912 ] and diluted to obtain a density corresponding to McFarland standard 1 (spectrophotometric equivalent ⁇ 3 x 10 8 CFU/mL).
- LSM lactic acid bacteria susceptibility test medium
- the suspension was further adjusted to 3 x 10 5 CFU/ml with LSM, and 100 ⁇ l were inoculated to wells of microtiter VetMIC plates for lactic acid bacteria (National Veterinary Institute of Sweden, Uppsala, Sweden). The plates were incubated at 37 °C for 48 h and the MIC was defined as the lowest concentration at which no growth was observed.
- MRS broth was inoculated with L. salivarius PS21603 strain in a 1% proportion. Each 2 h, during the next 24 h, OD 600 , pH and bacterial counts were registered, in duplicate. Briefly, a PS21603 overnight culture in MRS (Oxoid) was used to inoculate 100 mL fresh MRS broth in a 1% proportion, establishing an OD 600 initial point of 0.0. The broth with the inoculum was mixed in a magnetic stirrer before filling 2 24-well plates. Well plates were incubated at 37°C and the OD at 600 nm was determined every 2 hours for 24 h using a spectrophotometer (Anthos Zenyth 200rt microplate reader).
- L. salivarius PS21603 is able to reach the stationary phase after incubation at 37°C ( ⁇ 1 °C) in aerobiosis in 8 hours, reaching values at this point of 10 9 CFU/mL, making it a good strain for industrial production, reaching an acceptable biomass soon.
- it is able to rapidly acidify the medium in which it grows, reaching pH values of 4 after 8 hours of growth ( Figures 3-4 ).
- MRS broth tubes adjusted to different pH (2, 2.5, 3, 3.5 and 4) with HCl in a 3520 pH Meter (Jenway), were inoculated with L. salivarius PS21603 strain in 1% proportion.
- OD 600 was registered in Anthos Zenyth 200rt microplate reader, in triplicate. The resulting curves show the growth of the strain and its tolerance to acidity.
- Lactobacillus salivarius strain PS21603 is able to grow at pH above 3.5, albeit at a reduced rate. At a pH of 3, there is hardly any growth and below it growth is inhibited. Despite this, Lactobacillus salivarius PS21603 is able to survive for 2 h at low pH (pH 2), so it is expected that it has a high capacity to survive its passage through the stomach in an in vivo model, maintaining a number of viable cells enough to exert their effect on the animal's intestine.
- MRS broth tubes adjusted to NaCl concentrations (1, 2, 3, 4 and 5%), were inoculated with L. salivarius PS21603 strain in 1% proportion.
- OD 600 was registered in Anthos Zenyth 200rt microplate reader, in triplicate. The resulting curves show the growth of the strain and its tolerance to different osmotic pressure.
- Lactobacillus salivarius strain PS21603 presents a high tolerance to osmotic stress, represented in this case by the concentration of NaCl. Said strain is able to grow up to a concentration of 4% NaCl, which corresponds to high osmotic stress ( Figure 6 ). This data is applicable to lyophilization-rehydration cycles, which are a necessary step for production on an industrial scale. In conclusion, the strain PS21603 presents in vitro a high capacity to support the lyophilization-rehydration process.
- CFU colony-forming units
- Example 2 In vivo study in piglets
- To arm T1 feed supplemented with L. salivarius strain P21603 at a concentration of 10 9 CFU/kg of feed (dose of 10 9 CFU/day) was assigned.
- the concentration of 9 cytokines (IL-1 ⁇ , IL-4, IL-6, IL-8, IL-10, IL12, INF ⁇ , INF ⁇ and TNF ⁇ ) was studied to determine if there was a systemic effect on the immune system of the strain under study (Table 3).
- the changes observed in this analysis corresponded to the maturation of the immune system of the piglets. No effect of the strain on these cytokines was observed at a systemic level. No differences between associated with the administration of the strain were found.
- NA 3 10.42 (6.61. 12.05) --- 0.317 0.895 IL-8 1 5 60.27 (27.98, 281.98) 15 373.71 (231.69, 472.41) 0.001 14 171.35 (49.32, 282.92) 14 349.85 (272.39, 692.78) 0.002 14 152.31 (22.86, 314.97) 14 370.87 (335.12, 625.56) 0.007 0.763 0.955 IL-10 1 113.98 (113.98, 113.98) 1 153.26 (153.26, 153.26) --- 2 126.45 (88.85, 164.05) 0 NA (NA, NA) --- 0 NA (NA, NA) 0 NA (NA.
- Feed samples were diluted 10-times in peptone water (Oxoid) and digested in a masticator. Serial 10-fold dilutions were prepared in peptone water and plated in MRScys agar plates (Oxoid). Plates were incubated at 37°C, in anaerobiosis, for 48h. After the incubation, CFU were counted and bacterial concentration per feed gram calculated considering the dilution in which colonies were counted.
- strain L. salivarius PS21603 has been recovered at the concentration that was estimated to comply with the doses of 10 7 and 10 9 CFU/day, so that the animals were correctly supplemented during the study period.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
- The invention relates to the field of probiotic strains, in particular to a new probiotic strain of Lactobacillus salivarius, to compositions comprising said probiotic strain, and its use for the prevention and/or treatment of diseases, in particular of post-weaning diarrhea in pigs.
- Reduction of the lactation period has been an important factor in improving productivity in the swine industry. However, early weaning entails several problems since the piglet's digestive apparatus is undeveloped and low feed intake and diarrhea are common.
- Diarrhea (or scour) in piglets is one of the most common problems in pig farming affecting hundreds of millions of piglets born globally each year. It can result in reduced weight gain, high cost of treatment and frequent mortality. Piglets set back in health at an early age, tending to remain at a weight and performance disadvantage in later life. Therefore, diarrhea not only has a detrimental impact on piglet health, but on farm profitability.
- Piglet diarrhea caused by Escherichia coli (E. coli) strains is common within the first weeks after weaning, and also in the first weeks of life. Diarrhea in pre-weaned piglets (suckling pigs) can be fatal since piglets can become quickly dehydrated and mortality rates are high.
- Weaning is a critical period in a piglet's life. It must cope with separation from the sow, the transition from highly digestible milk to a less digestible and more complex solid feed, a new environment, movement and separation from littermates, and exposure to unfamiliar pigs. These stress factors can lead to reduced feed intake and reduced piglet growth. Additionally, the newly-weaned pigs' immune and digestive systems are still maturing, making the piglet more susceptible to antigenic challenges (nutritional or microbial), which can lead to inflammatory responses. Inflammation induces a negative impact on the digestive and absorptive capabilities of the gut, and overall gut health creating an opportunity for an animal to become more susceptible to pathogens. An animal whose reduced feed intake is poor at the time of pathogen exposure will become sick. The absence of feed in a piglet's gut results in a microbial imbalance, leading to higher occurrences of diseases. During this period, post-weaning diarrhea (PWD) is very frequent. PWD generally affects pigs during the first two weeks after weaning and is characterized by sudden death or diarrhea, dehydration and growth retardation in surviving piglets. PWD is commonly associated with the proliferation of E. coli in the pig intestine, typically belonging to serogroups 0149, O8, 0138, 0139, 0141, 0147, and 0157. Feed intake is usually reduced initially after weaning and the pig may develop anorexia of variable duration and extent between farms, depending on livestock management and the nature of the feed. Underfeeding during weaning reduces growth performance of pigs and contributes to intestinal inflammation and adversely affects villous height and crypt depth. This morphological disruption of the intestinal mucosa promotes the creation of an ideal environment for the multiplication of bacteria such as E. coli and allows toxins and bacteria to cross the epithelium as a result of this inflammation.
- Antibiotics, such as colistin, are widely used for the control of PWD in pigs. However, in humans this antibiotic is considered as one of the last therapeutic options for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Since food producing animals, and in particular pigs, have been singled out as the most potential reservoirs for spread and amplification of colistin resistance, scientists and regulatory agencies have recommended reducing the use of said antibiotic in animal production.
- Other strategies used in pigs for controlling PWD are feed supplements such as zinc oxide, organic acids (such as citric, fumaric, lactic, propionic, benzoic and formic acids), prebiotics (such as inulin, oligosaccharides, e.g. galactooligosaccharides and fructooligosaccharides), probiotics (such as L. rhamnosus and L. acidophilus), dehydrated porcine plasma, antimicrobial peptides (such as lactoferrin, cecropin, defensing, plectasin and bacteriocins), specific egg yolk antibodies, bacteriophages and probiotics.
- Probiotics are defined by the World Health Organization as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Probiotic products may be formulated as capsules, tablets, powders (which are regulated as a dietary supplement), and a feed or food ingredient (e.g., yogurts, kefirs), or as a drug. Probiotics may exert a wide range of beneficial effects, such as balancing the host gut microbiota and interacting with the innate and adaptive immune system, which may promote resistance against pathogens. The most commonly used probiotics are Lactobacillus and Bifidobacterium species, followed by the genera Streptococcus, Enterococcus, Propionibacterium, Bacillus, and Escherichia coli. In addition, some yeast species are used as probiotics, for example, Saccharomyces boulardii and Saccharomyces cerevisiae are frequently used to treat gastrointestinal disorders.
- Lactobacillus salivarius is a species commonly isolated from the gastrointestinal tract of humans and animals with potential probiotic properties. Results of previous studies have shown a considerable functional diversity existing both in the chromosome and in the plasmids of different strains. A variety of bacteriocins with different spectra of activity against pathogens are coded in these plasmids [Harris et al., Microb Genom., 2017, 3, e000115]. The production of these antibacterial proteins is widely distributed within the strains of this species, providing them with the ability to modulate the intestinal microbiota and reduce the impact of pathogens, such as Listeria monocytogenes [O 'Shea et al., Gut Microbes, 2012, 3(5), 468-473]. Other strains of L. salivarius have shown activity against Streptococcus mutans, which is involved in the production of caries [Sañudo et al., Arch Oral Biol., 2017, 84, 58-63], and against Aggregatibacter actinomycetemcomitans, which is involved in periodontal disease [Sajedinejad et al., Probiotics Antimicrob Proteins, 2018, 10, 485-495]. At vaginal level, strains of L. salivarius present antimicrobial activity against Gardnerella vaginalis and Candida albicans, which are implicated in vulvovaginitis [Kang et al., Probiotics Antimicrob Proteins, 2018, 10, 343-349]. Other L. salivarius strains have shown activity against Staphylococcus aureus [Heikkilä and Saris, J Appl Microbiol., 2003, 95, 471-478; Kang et al., Pathog Dis., 2017, 75(2). doi:10.1093/femspd/ftx009], S. epidermidis [Arroyo et al., Clin Infect Dis., 2010, 50, 1551-1558] and against enterobacteria [Abhisingha et al., Probiotics Antimicrob Proteins, 2018, 10, 218-227].
- In animals, L. salivarius has been effective in the control of Salmonella, Brachyspira pilosicoli and Campylobacter jejuni in poultry farms [Mappley et al., Appl Environ Microbiol., 2011, 77, 5402-5411; Ghareeb et al., Poult Sci., 2012, 91, 1825-1832; Yamakazi et al., Br Poult Sci., 2012, 53, 183-189]. In pigs, the administration of L. salivarius together with Bacillus subtilis has improved the immune status of the intestinal mucosa of the piglets, which is a reinforcing measure to avoid post-weaning diarrhea [Zhang et al., Curr Microbiol., 2011, 62, 1623-1631; and Deng et al., Res V et Sci., 2013, 94, 62-68]. Despite these positive results, interaction of Lactobacillus with pre-existent microbiota may also have negative effects, as evidenced by the study conducted by Trevisi et al. [Animal, 2011, 9(9), 1354-1360]. Lactobacillus rhamnosus GG did not only fail to prevent or reduce the detrimental effect of E. coli infection on the growth performance and health statues of weaned piglets, but also interacted negatively with the intestinal barrier.
- In summary, post-weaning diarrhea (PWD) is a serious threat for the swine industry worldwide. Alternatives to antibiotic treatments are necessary to avoid transfer of antibiotic resistance to humans. Thus, there remains a need for new treatments of diarrhea in piglets, in particular of PWD.
- The inventors have isolated and characterized a probiotic strain of Lactobacillus salivarius (PS21603) isolated from the intestine of a wild boar, which has surprisingly been found to reduce the fecal E. coli concentration, to be useful for the prevention and/or treatment of diarrhea in a mammal, in particular post-weaning diarrhea in piglets.
- As shown in the examples, the Lactobacillus salivarius strain PS21603 of the invention has a great inhibitory activity of Escherichia coli, said Lactobacillus salivarius PS21603 strain has not shown any resistance to antibiotics, and animals treated with said strain have shown improved intestinal morphology (ratio of villous height to crypt depth and length of the small and large intestine). Therefore, the Lactobacillus salivarius strain PS21603 of the invention has shown a high potential for the treatment and/or prevention of diarrhea in a mammal, in particular PWD in pigs. The Lactobacillus salivarius PS21603 strain has been deposited at the Colección Española de Cultivos Tipo (CECT) and has been given accession number CECT 9673.
- Thus, in one aspect, the present invention is directed to a strain of Lactobacillus salivarius PS21603 or a variant thereof having at least 95% identity with this strain, wherein the variant strains are obtained by using the deposited strain as starter material, and wherein the variant strains retain or further improve the activity of the strain Lactobacillus salivarius PS21603. Preferably the strain has at least 97% identity with the strain of Lactobacillus salivarius PS21603.
- In another aspect, the invention also relates to a composition comprising the strain as defined above.
- In further aspect, the invention also relates to the strain or composition as defined above for use as a probiotic or for use as a prevention and/or therapeutic agent.
- In another aspect, the invention is directed to the strain or the composition as defined above, for use in the prevention and/or treatment of diarrhea in a mammal, in particular for the treatment and/or prevention of post-weaning diarrhea (PWD) in pigs.
- In an additional aspect, the invention is directed to the strain or the composition as defined above, for use in improving performance of a mammal animal.
-
-
Figure 1 shows the growth curve of the L. salivarius PS21603, represented as OD600 variation of the OD600 (optical density measured at 600 nm) over time (h). S is the standard error and R is the correlation coefficient. -
Figure 2 represents the correlation between the OD600 and the L. salivarius PS21603 concentration (expressed as log(CFU/mL). S is the standard error and R is the correlation coefficient. -
Figure 3 shows the evolution of pH of the L. salivarius PS21603 growth medium with time (h). S is the standard error and R is the correlation coefficient. -
Figure 4 represents the correlation of L. salivarius PS21603 concentration (log (CFU/mL)) with acid production (pH). S is the standard error and R is the correlation coefficient. -
Figure 5 shows the evolution of OD600 over time (h) for L. salivarius PS21603 at different pH. -
Figure 6 shows the evolution of OD600 over time (h) for L. salivarius PS21603 at different NaCl concentrations. -
Figure 7 represents the bacterial concentration (log (CFU/mL)) of L. salivarius PS21603 and E. coli CECT501 at 0 h and 24 h of co-culture of both strains. - In the present invention, the term "probiotic" means a microorganism that exerts beneficial effects on the health of the host. It can be a live microbial fed supplement or medicament that beneficially affects the host by improving its microbial balance, a microbial preparation that contains live or dead bacteria, or a combination of both. Hosts suitable in the context of the invention includes any mammal, such as pigs, horses, cows, goats, ewes, dogs, cats, rats, mice and primates, such as human beings; more preferably pigs.
- The term "pig" or "swine" includes domestic pigs and wild boars of any age, preferably piglets and weaners, both males and females. In particular, "piglets" refers to young pigs, such as from birth until weaning, which in pig farming generally takes place at the age of 2-4 weeks; and "weaners" refers to pigs from weaning until the age of about 10 weeks.
- The strain of Lactobacillus salivarius according to the invention is referred to as Lactobacillus salivarius PS21603 or L. salivarius PS21603. The strain L. salivarius PS21603 has been deposited by Probisearch SLU,
Calle Santiago Grisolía 2, Tres Cantos, Spain in accordance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure at the Colección Española de Cultivos Tipo (CECT) on 5 June 2018 and has been given Accession Number CECT 9673. - The term "strain" is well-known in the field and means a genetic variant or subtype of a microorganism. A "variant" or "mutant" of a strain refer to any naturally-occurring or specifically developed strain obtained from the reference strain L. salivarius PS21603, mainly by mutation, that maintains or enhances the properties of the reference strain. Thus, in the present case, the invention relates to variants of the reference strain in which one or more of the following properties associated to the L. salivarius PS21603 strain is preserved or enhanced:
- prevent or reduce scours in piglets or weaners,
- increase piglet or weaner weight,
- reduce piglet or weaner fecal E. coli concentration,
- reduce E. coli concentration in the 24-hour co-culture with the E. coli strain having accession number CECT 501 (given by the Colección Española de Cultivos Tipo), with serotype O149: K91, K88a, c: H10,
- increase the length of the small and/or large intestine of piglets or weaners, and
- improve the ratio of villous height to crypt depth of the intestine of piglets or weaners.
- As used herein, the reference to that the variant strain maintains the properties of the reference strain L. salivarius PS21603 means that, while not showing an activity of 100% of the activity of the reference strain L. salivarius PS21603 from which it derives, the property is substantially preserved so that the variant shows at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, at least 90%, at least 80%, at least 70%, at least 60%, at least 50% of the activity of the L. salivarius PS21603 strain from which it derives.
- The person skilled in the art will decide upon the adequate method to be employed for determining each of the properties mentioned above for the strains, in particular using the methods described in the examples of the present application.
- The present invention also relates to strains of L. salivarius having at least 95 % identity with the 16S rRNA sequence of the L. salivarius PS21603 strain, which is described in the examples [reference Stackebrandt & Goebel, 1994: "Taxonomic Note: A Place for DNA-DNA Reassociation and 16s rRNA Sequence Analysis in the Present Species Definition in Bacteriology" Int. J. Syst. Bacteriol. 44:846-849].
- In a preferred embodiment, the strain according to the present invention has at least 97 % identity with the 16S rRNA sequence of the L. salivarius PS21603 strain, more preferably at least 98% identity, more preferably at least 99% identity. In another preferred embodiment, the strain according to the present invention has 100% identity with the 16S rRNA sequence of the L. salivarius PS21603 strain, i.e. the strain according to the present invention is the Lactobacillus salivarius PS21603 strain.
- The strains of the invention, as demonstrated in the examples, have sufficient resistance to the conditions of the acidic microenvironment of the gastrointestinal tract so that said strains may survive passage through the gastrointestinal tract. The strains have also shown good resistance to osmotic stress, which allows them to withstand lyophilization-rehydration processes used in industrial production of probiotics.
- The strain of the present invention may be alive or inactivated. Alive microorganisms produce a complete array of antigens, reproduce to increase the number of such organisms in the intestinal environment to better stimulate an immune response. Thus, in a preferred embodiment, the strain of the invention is alive.
- As used herein, the term "inactivated" refers to a dead or inactivated cell of a microorganism which is no longer capable to form a single colony on a plate having medium specific for said microorganism, and it also encompasses lysates, fractions or extracts of the microorganism. The inactivation of a cell refers to a process of transforming a cell from viable to non-viable. The terms "viable", "alive" or "viability", as used herein, refer to the ability of a cell to maintain itself or recover its potentialities and survive until they are able to divide. Thus, a cell that is viable or alive indicates that the cell is able to survive and divide; conversely, a cell that is non-viable indicates that the cell is not able to survive and divide. It will be appreciated that non-viable cells include dead cells.
- Viability can be determined by a number of assays that are conventional in the art. These include cytolysis or membrane leakage assays, such as the lactate dehydrogenase assay, the propidium iodide assay, the trypan blue assay and the 7-aminoactinomycin D assay, as well as genomic and proteomic assays that test the activation of stress pathways using DNA microarrays and protein chips. Viability can also be determined by checking the absence of cells after their culture in an appropriate culture medium.
- In another aspect, the present invention relates to a composition comprising the L. salivarius PS21603 strain of the invention, or variant thereof.
- Preferably, the compositions of the invention comprises the L. salivarius PS21603 strain of the invention or variant thereof and a physiologically acceptable carrier or excipient and/or further ingredients as described further below. Preferably, the L. salivarius strain according to the invention is present in freeze-dried form.
- The term "composition", as used in the present invention relates to any composition of matter comprising the strain of the invention, i.e. L. salivarius PS21603 strain or variant thereof.
- In a preferred embodiment, the composition of the invention comprises the L. salivarius PS21603 strain or variant thereof and a veterinary or pharmaceutically acceptable excipients. These compositions can also be named as "veterinary composition", "veterinary product", "pharmaceutical composition" or "pharmaceutical product".
- As used in the present invention, the expressions "veterinary" and "pharmaceutical" refer to the same type of product or ingredient but the first one being intended for animal use and the second one being intended for human use.
- As used in the present invention, the expressions "veterinary composition" or "veterinary product" are used herein interchangeably and refer to a formulation which has been adapted to administer a predetermined dose of one or several therapeutically useful agents, i.e. the strains of the invention, to a mammal animal, preferably pigs, in which a direct or indirect therapeutic effect of the composition is sought out. The veterinary composition of the invention contains a therapeutically effective amount of the Lactobacillus salivarius PS21603 strain of the invention or a variant thereof, which is understood herein as an amount capable of providing a therapeutic effect, and which can be determined by the person skilled in the art by commonly used means.
- As used in the present invention, the expressions "pharmaceutical composition" or "pharmaceutical product" are used herein interchangeably and refer to a formulation which has been adapted to administer a predetermined dose of one or several therapeutically useful agents to a mammal, preferably a piglet, in which a direct or indirect therapeutic effect of the composition is sought out. The pharmaceutical composition of the invention contains a therapeutically effective amount of the Lactobacillus salivarius PS21603 strain of the invention or a variant thereof, which is understood herein as an amount capable of providing a therapeutic effect, and which can be determined by the person skilled in the art by commonly used means.
- The "veterinary acceptable excipient" and "pharmaceutical acceptable excipient" refer to a diluent or carrier with which the active ingredient, i.e. the strains of the invention, is administered. Acceptable excipients for therapeutic use are well known in the veterinary and pharmaceutical art, and are described, for example, in Remington: The Science and Practice of Pharmacy, Lippincott Williams and Wilkins (22nd Ed., 2012). The choice of veterinary and pharmaceutical excipient can be selected with regard to the intended route of administration and standard pharmaceutical and veterinary practice. For example, such pharmaceutical and veterinary excipients include, but are not limited to, water, glucose, lactose, sucrose, mannitol, maltodextrin, (resistant) starch, cellulose or cellulose derivatives, e.g. methylcellulose, magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate and the like; preferably maltodextrin. Water or aqueous solutions of saline solution and aqueous dextrose and glycerol solutions are preferably used as excipients. The pharmaceutical and veterinary compositions of the invention may comprise as - or in addition to - the excipients mentioned above any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilizing agent(s). Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical and veterinary compositions. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may also be used. There may be different composition/formulation requirements depending on the different delivery systems.
- In a preferred embodiment, the composition of the invention comprises maltodextrin as the veterinary or pharmaceutically acceptable excipient.
- In a particular embodiment the strain of the invention is present in a foodstuff. These compositions can also be named as terms "feed product", "feed composition", "food product" or "food composition". These compositions relate to a feed or food that beneficially affects one or more functions of the body, so as to provide better health and wellness. Accordingly, such a feed or food product may be intended for the prevention and/or treatment of a disease or a disease causing factor. Therefore, these compositions can also be named as functional feed or food for particular nutritional purposes, or veterinary feed.
- As used in the present invention, the expressions "feed" and "food" and refer to a foodstuff but the first one being intended for animal use and the second one being intended for human use. In particular, the term "feed" refers to a commercial feed which is formulated according to the specific requirements of the target animal.
- Non-limiting examples of suitable foodstuffs which can be used in the present invention are animal feed, including feed premix, final feed product, pellets, cereals (such as corn, oats and barley), fermented cereal based products, other cereal based powders, soybean, copra, straw, grass, sugar beet waste, fish meal, meat and bone meal, seeds, bread, cakes, semi- or synthetic diet formulations, infant formulae, clinical nutrition formulae, flours. Preferably the foodstuff is an animal feed, such as pig feed.
- The effective amount of colony forming units (CFU) for each strain in the composition of the invention will be determined by the skilled person and will depend upon the final formulation and the times per day it will be administered. Preferably, the strain of the invention is present in the compositions of the invention in an amount that provides about 105 CFU/day to about 1011 CFU/day, preferably in an amount from about 106 CFU/day to about 1010 CFU/day, more preferably in an amount from about 107 CFU/day to about 109 CFU/day.
- The term CFU refers to "Colony Forming Units". Quantification of bacteria in a given sample is routinely achieved by counting the total number of colony-forming units (CFUs) grown on an agar plate from serial dilutions, expressed as CFU per gram or mL of the original sample. This yields an estimate of the number of cells present based on a skilled interpretation of the number of colonies on a plate.
- A particularly preferred composition of the invention comprises the Lactobacillus salivarius PS21603 strain of the invention and maltodextrin. Preferably, the composition comprises the Lactobacillus salivarius PS21603 strain of the invention and maltodextrin, wherein the amount of the Lactobacillus salivarius PS21603 strain of the invention is from 106 CFU to 108 CFU per gram (g) of composition.
- Another particularly preferred composition of the invention comprises the Lactobacillus salivarius PS21603 strain of the invention, maltodextrin and an animal feed, such as pig feed. Preferably, said compositions of the invention comprise from about 105 CFU/kg to about 1011 CFU/kg, preferably from about 106 CFU/kg to about 1010 CFU/kg, more preferably in from about 107 CFU/kg to about 109 CFU/kg, wherein the amounts are expressed as CFU of the strains of the invention per kg of feed.
- The composition according to the invention may comprise further probiotics, apart from the L. salivarius PS21603 strain of the invention or a variant thereof as described above. Probiotics have beneficial effects on the immune system, hence the combination with probiotics will have a superior effect on immune system. Preferably, the further probiotics are selected from the group consisting of Lactobacillus and Bifidobacterium.
- The composition of the present invention may further contain prebiotics. Prebiotics may support the growth of probiotics before they are rendered non-replicating. "Prebiotic" means non-digestible food substances that promote the growth of health beneficial microorganisms and/or probiotics in the intestines. They are not broken down in the stomach and/or upper intestine or absorbed in the GI tract of the person ingesting them, but they are fermented by the gastrointestinal microbiota and/or by probiotics. Preferably, they may be selected from the group consisting of oligosaccharides, optionally containing fructose, galactose, mannose; dietary fibers, in particular soluble fibers, soy fibers; inulin; or mixtures thereof. Preferred prebiotics are fructo-oligosaccharides, galactooligosaccharides, isomalto-oligosaccharides, xylo-oligosaccharides, arabino-xylo oligosaccharides, mannan-oligosaccharides, oligosaccharides of soy, glycosylsucrose, lactosucrose, lactulose, palatinose-oligosaccharides, malto-oligosaccharides, gums and/or hydrolysates thereof, pectins and/or hydrolysates thereof.
- As evidenced by the examples below, the strains and compositions of the invention are safe and have an important beneficial effect. In an in vivo animal study, the strain of the invention prevented scours, increased animal weight, reduced fecal E. coli concentration, increased the length of the small and large intestine, and improved the ratio of villous height to crypt depth.
- Thus, in a further aspects, the present invention relates to a strain or a composition as previously defined for use as a probiotic, as well as a prevention and/or therapeutic agent.
- In a further aspect, the invention relates to a strain or a composition as previously defined, for use in the prevention and/or treatment of diarrhea in a mammal, preferably in a pig,
- In one embodiment, the invention relates to a strain or a composition as previously defined, for use in the prevention and/or treatment of post-weaning diarrhea in a mammal, preferably in a pig. In particular, the strain is for use in the prevention and/or treatment by diarrhea caused by an E. coli infection.
- As used herein the terms "treat", "treatment", or "treatment of' refers to reducing the potential for a certain disease or disorder, reducing the occurrence of a certain disease or disorder, and/or a reduction in the severity of a certain disease or disorder, preferably, to an extent that the subject no longer suffers discomfort and/or altered function due to it. It also refers to mitigating or decreasing at least one clinical symptom and/or inhibition or delay in the progression of the condition and/or prevention or delay of the onset of a disease or illness. It also means prolonging survival as compared to expected survival if not receiving the treatment.
- The term "prevention", "preventing" or "prevent", as used herein, refers to avoiding the appearance of a certain disease or disorder. The prevention can be complete (e.g. the total absence of a disease). The prevention can also be partial, such that for example the occurrence of a disease in a subject is less than that which would have occurred without the administration of the combination or composition of the present invention. Prevention also refers to reduced susceptibility to a clinical condition. The prevention also includes reducing the risk of suffering the disease.
- The strain and compositions of the invention also improve performance of an animal. The term "performance" refers to the productivity of an animal, such as a pig, measured by one or more of the following parameters: scours, mortality, number of animals born, number of animals born alive, litter birth weight, and immune system function. An improved performance refers to an improvement in at least one of the previously listed parameters.
- Accordingly, a further aspect the invention relates to a strain or a composition as previously defined for use in improving performance of a mammal animal, preferably a pig.
- The strains and composition for use in the present invention described above are preferably administered enterically, more preferably orally. The strain and composition for use according to the invention may be administered in a single daily dose or multiple doses per day, such as at least 2 doses per day, at least 3 doses per day, at least 4 doses per day. Preferably, the strain and composition according to the invention are administered 1, 2 or 3 doses per day. The person skilled in the art will be able to adjust the therapeutically effective dose and/or the prophylactic effective dose appropriately. The precise dose depends on a number of factors such as the mammal's health and weight. Preferably the strain and composition of the invention are administered in an amount that provides a dose of the strain of 105 CFU/day to about 1011 CFU/day, preferably in an amount from about 106 CFU/day to about 1010 CFU/day, more preferably in an amount from about 107 CFU/day to about 109 CFU/day to the mammal receiving said strain or composition.
- In an embodiment of the invention the strain or composition of the invention is for use in a pig. In a preferred embodiment, the pig is a piglet or a weaner, even more preferably a weaner.
- Preferably, the strain and composition of the invention is administered for about 2 to about 6 weeks, more preferably for about 3 to about 5 weeks, still more preferably for about 4 weeks (or about 1 month). Preferably, the strain and composition of the invention is administered during the weaning period, more preferably for about 2 to about 6 weeks after weaning, even more preferably for about 3 to about 5 weeks after weaning, still more preferably about 4 weeks after weaning (or about 1 month after weaning).
- Lactobacillus salivarius PS21603 was isolated from the intestine of a wild boar. After the necropsy of the animal, gut content was recovered, diluted and plated in MRS (supplemented with cysteine (MRScys) medium. The incubation was done in anaerobic conditions, at 37°C for 48h.
- The strain was identified at the species level as Lactobacillus salivarius by PCR amplification of a section of a 16S rRNA gene variable region using primers plb16 (5'-AGAGTTTGATCCTGGCTCAG-3', SEQ ID NO: 1) and mlb16 (5'-GGCTGCTGGCACGTAGTTAG-3', SEQ ID NO: 2) [Kullen et al., Journal of Applied Microbiology, 2000, 89, 511-518]. PCR conditions were as follows: 96 °C for 30 s, 50 °C for 30 s and 72 °C for 45 s (35 cycles) and a final extension at 72 °C for 4 min. Amplified fragments were purified using the NucleoSpin Extract II (Macherey-Nagel Gmb; Düren, Germany) and sequenced using the primers cited above on an ABI 377A automated sequencer (Applied Biosystems, Foster City, USA). The sequences were compared with those deposited in the EMBL database using BLAST algorithm (http://www.ncbi.nlm.nih.gov/BLAST)
-
- The identification was confirmed by Matrix Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) mass spectrometry using a Vitek-MS™ instrument (BioMérieux, Marcy l'Etoile, France) in the facilities of Probisearch (Tres Cantos, Spain). Briefly, a portion of a bacterial colony (∼1 uL) was directly spotted onto a MALDI sample plate. Then, it was overlaid with 1 (µL of a saturated solution of α-cyano-4-hydroxycinnamic acid in acetonitrile (28%), and allowed to dry at room temperature. A mean spectrum was constructed with at least 50 m/z spectra profiles and used for the identification by comparison with the spectra contained in the Myla database (Biomerieux). Identification was defined as a 99% match to the species-specific m/z values in the database.
- The strain could be differentiated from other L. salivarius strains of our own collection by genotyping by randomly amplified polymorphic DNA (RAPD), pulsed-field gel electrophoresis (PFGE) analyses and the complete genome sequence.
- The complete genome of the strain L. salivarius PS21603 has been sequenced and analyzed.
- Following plate microdilution method referred by EFSA, the MIC of the 8 antibiotics included in this study was determined on L. salivarius PS21603 cultures grown overnight in lactic acid bacteria susceptibility test medium (LSM) [Klare et al., Journal of Antimicrobial Chemotherapy, 2005, 59, 900-912] and diluted to obtain a density corresponding to McFarland standard 1 (spectrophotometric equivalent ∼ 3 x 108 CFU/mL). The suspension was further adjusted to 3 x 105 CFU/ml with LSM, and 100 µl were inoculated to wells of microtiter VetMIC plates for lactic acid bacteria (National Veterinary Institute of Sweden, Uppsala, Sweden). The plates were incubated at 37 °C for 48 h and the MIC was defined as the lowest concentration at which no growth was observed.
- Results from the different antibiotic susceptibility tests were interpreted according to the cut-off levels proposed by the European Food Safety Authority (EFSA, 2017). According to these values, the lactobacillus was sensitive to all the antibiotics tested in this study with the exception of kanamycin, an aminoglycoside antibiotic (Table 1). Bacteria of the genus Lactobacillus, like other anaerobic bacteria, tend to be intrinsically resistant to aminoglycosides. This fact implies a certain level of resistance to this group of antibiotics, among which we find gentamicin, kanamycin and streptomycin (EFSA BIOHAZ Panel, 2017, Ricci et al., EFSA Journal, 2017, 15(3), 4664, 177 pp., doi 10.2903/j.efsa.2017.4664). Resistance to these antibiotics has been registered by several authors (Charteris et al., J Food Prot, 1998, 61(12), 1636-1643; Danielsen and Wind, Int J Food Microbiol, 2003, 82(1), 1-11; Zhou et al., Int J Food Microbiol, 2005, 98(2), 211-217; Korhonen et al., J Appl Microbiol, 2007, 103(6), 2496-2503; Guimonde et al., Front Microbiol, 2013, 4, 202, doi: 10.3389/fmicb.2013.00202; Jaimee and Halami, Appl Microbiol Biotechnol, 2016, 100(3), 1137-1151, doi: 10.1007/s00253-015-7184-y), suggesting the existence of an intrinsic resistance. In general, the lack of oxidative metabolism and a low membrane potential (Δψ), which imply a low rate of electron transport and a decrease in the internalization rate of antibiotic molecules. These membrane characteristics are responsible for the resistance in the genus Lactobacillus to the aminoglycosides (Bryan and Kwan, J Antimicrob Chemother, 1981, 8 Suppl D, 1-8; Taber et al., Microbiol Rev, 1987, 51(4), 439-457; Schlessinger, Clin Microbiol Rev, 1988, 1, 54-59, https://doi.org/10.1128/CMR.1.1.54; Elkins and Mullis, Appl Environ Microbiol, 2004, 70(12), 7200-7209, doi: 10.1128/AEM.70.12.7200-7209.2004; Steyger, The Volta Review, 2005, 105(3) (monograph), 299-324; Jana and Deb, Appl Microbiol Biotechnol, 2006, 70, 140-150, doi 10.1007/s00253-005-0279-0; Ramírez and Tolmasky, Drug Resist Updat, 2010, 13(6), 151-171, doi:10.1016/j.drup.2010.08.003; Abede et al., Europ. J. Appl. Sci., 2016, 8(5), 301-310, doi: 10.5829/idosi.ejas.2016.8.5.1143).
- In addition to the antibiotic sensitivity pattern analysis by the plate microdilution technique, the complete genome sequence of the strain was analyzed with The Comprehensive Antibiotic Resistance Database (CARD), a bioinformatic tool recommended by the EFSA, not finding genes related to any mechanism of resistance to known antibiotics.
Table 1. Minimum inhibitory concentrations (MICs), and EFSA cut-off values (µg/ml), of antibiotics against L. salivarius PS21603. Antibiotic Cut-off values* MICs (L. salivarius PS21603) Ampicillin 4 1 Gentamicin 16 4 Kanamycin 64 128 Streptomycin 64 64 Erythromycin 1 0.12 Clindamycin 1 0.12 T etracyclin 8 0.5 Chloramphenicol 4 1 *EFSA (2017); Ricci et al., EFSA Journal, 2017, 15(3), 4664; FEEDAP panel EFSA 2017 - MRS broth was inoculated with L. salivarius PS21603 strain in a 1% proportion. Each 2 h, during the next 24 h, OD600, pH and bacterial counts were registered, in duplicate. Briefly, a PS21603 overnight culture in MRS (Oxoid) was used to inoculate 100 mL fresh MRS broth in a 1% proportion, establishing an OD600 initial point of 0.0. The broth with the inoculum was mixed in a magnetic stirrer before filling 2 24-well plates. Well plates were incubated at 37°C and the OD at 600 nm was determined every 2 hours for 24 h using a spectrophotometer (Anthos Zenyth 200rt microplate reader). In parallel, every 2 hours, 2 wells were recovered to measure pH and to count cell numbers. pH measurement was performed in a 3520 pH Meter (Jenway). To perform bacterial counts, each sample was 10-fold diluted, plated in MRS agar plates and incubated at 37°C for 48h in aerobic conditions. After incubation, colony forming units (CFU) were counted and bacterial concentration was calculated. Results were represented as curves, showing the growth evolution of the strain. In addition, math models were calculated to predict CFU/mL and pH based on OD600 values in the Curve Expert Software (Hyams Development).
- As shown in
Figures 1 and 2 , L. salivarius PS21603 is able to reach the stationary phase after incubation at 37°C (± 1 °C) in aerobiosis in 8 hours, reaching values at this point of 109 CFU/mL, making it a good strain for industrial production, reaching an acceptable biomass soon. In addition, it is able to rapidly acidify the medium in which it grows, reaching pH values of 4 after 8 hours of growth (Figures 3-4 ). - MRS broth tubes, adjusted to different pH (2, 2.5, 3, 3.5 and 4) with HCl in a 3520 pH Meter (Jenway), were inoculated with L. salivarius PS21603 strain in 1% proportion. During the next 24h, OD600 was registered in Anthos Zenyth 200rt microplate reader, in triplicate. The resulting curves show the growth of the strain and its tolerance to acidity.
- As shown in
Figure 5 , Lactobacillus salivarius strain PS21603 is able to grow at pH above 3.5, albeit at a reduced rate. At a pH of 3, there is hardly any growth and below it growth is inhibited. Despite this, Lactobacillus salivarius PS21603 is able to survive for 2 h at low pH (pH 2), so it is expected that it has a high capacity to survive its passage through the stomach in an in vivo model, maintaining a number of viable cells enough to exert their effect on the animal's intestine. - MRS broth tubes, adjusted to NaCl concentrations (1, 2, 3, 4 and 5%), were inoculated with L. salivarius PS21603 strain in 1% proportion. During the next 24h, OD600 was registered in Anthos Zenyth 200rt microplate reader, in triplicate. The resulting curves show the growth of the strain and its tolerance to different osmotic pressure.
- Lactobacillus salivarius strain PS21603 presents a high tolerance to osmotic stress, represented in this case by the concentration of NaCl. Said strain is able to grow up to a concentration of 4% NaCl, which corresponds to high osmotic stress (
Figure 6 ). This data is applicable to lyophilization-rehydration cycles, which are a necessary step for production on an industrial scale. In conclusion, the strain PS21603 presents in vitro a high capacity to support the lyophilization-rehydration process. - The ability of the L. salivarius PS21603 strain to inhibit E. coli was investigated. PS21603 strain and E. coli CECT501 strain were incubated separately in MRS and BHI broth, respectively, under aerobiosis conditions until OD600 = 0.6. Aliquots of the PS21603 strain culture were mixed with equal volumes of each of the pathogen cultures in BHI and MRS, and incubation was carried out in aerobic conditions at 37°C. Samples from the mixed cultures were plated at the beginning and at the end of the incubation process on the appropriate media. Plates were incubated at 37°C for 48h and colony-forming units (CFU) counted. The experiment was performed in triplicate.
- In the 24-hour co-culture with the E. coli strain having accession number CECT501 (given by the Colección Española de Cultivos Tipo), with serotype O149: K91, K88a, c: H10, the presence of L. salivarius PS21603 induces a reduction of 5 logarithmic units of the pathogen (
Figure 7 ). This is a clear inhibition of the growth of this E. coli strain, whether starting at the same concentration or with a 10-fold lower concentration, showing the utility of the L. salivarius PS21603 strain in enhancing the resistance to E. coli infection which is the main cause of post-weaning diarrhea [Huang et al., Asian-Aust J Anim Sci, 2004, 17(3), 401-409; Dowarah et al., Livestock Science, 2017, 195, 74-79]. - A 28-day study was carried out in piglets after weaning on a farm owned by PigCHAMP, a world leader in pig research. This farm, located in the municipality of Aguilafuente (Segovia, Spain), is a commercial farm that is adapted for animal experimentation. The study was authorized by the Junta de Castilla y León (Spain).
- The study included a total of 384 animals divided into three study arms, two supplemented with the strain L. salivarius PS21603 at different doses, and a third control arm, which were administered the diet without supplementation. The animals were randomized among the three arms that were homogeneous at the beginning of the study. The total duration of the study was 28 days, so that the animals that started the study at 28 days of age ended at 56 days of age. To arm T1, feed supplemented with L. salivarius strain P21603 at a concentration of 109 CFU/kg of feed (dose of 109 CFU/day) was assigned. To arm T2, feed supplemented with L. salivarius strain P21603 at a concentration of 107 CFU/Kg of feed (dose of 107 CFU/day) was assigned. To arm T3, control diet, without supplementation was assigned. Each of the arms was divided into pens, assigned randomly within the farm rooms. The L. salivarius strain P21603 was administered lyophilized without encapsulating and vehiculated in maltodextrin to give volume to the preparation.
- To monitor the growth and fattening of the animals, the production data of each animal was recorded at the beginning (day 0), at day 7, at
day 14 and at the end of the study (day 28). During the intervention period, samples of feces and blood of 16 animals per arm were collected at the beginning and at the end of the study. Once the study was finished, 6 animals of each group were sacrificed for the macroscopic and histological analysis of the small and large intestine. Samples of feed were taken from each batch prepared for each group of animals in order to know the actual concentration administered of the strain. - All the animals belonging to the batch used in the study were exceptional in terms of general health and, specifically, intestinal health. There were no cases of diarrhea in any of the arms and all grew above the mean values observed in the history of the farm, with no differences in weight gain with respect to the group assigned to the animals (Table 2). This makes the results obtained in this trial especially relevant, since we consider that all the findings are due to the effect of the strain in a perfectly healthy population, showing the safety and tolerance of the strain.
- The feces' samples collected at the beginning (W0) and at the end of the study (W4) were plated in McK, a solid medium specific for the growth of enterobacteria, to assess E. coli counts.
- The animals that received the dose of 109 CFU/day presented a significant reduction of the E. coli counts in feces when comparing with the control group. Those animals that received the
dose 107 CFU/day showed a tendency of the E. coli reduction (Table 3). No bacteria of the genus Salmonella were detected in any of the samples. - In the blood samples, the concentration of 9 cytokines (IL-1β, IL-4, IL-6, IL-8, IL-10, IL12, INFα, INFγ and TNFα) was studied to determine if there was a systemic effect on the immune system of the strain under study (Table 3). The changes observed in this analysis corresponded to the maturation of the immune system of the piglets. No effect of the strain on these cytokines was observed at a systemic level. No differences between associated with the administration of the strain were found.
- The macroscopic analysis performed at the necropsy of the sacrificed animals showed an enlargement of the small and large intestine in the study groups which received diet supplemented with the strain L. salivarius PS21603 (Table 4). In addition, this effect was dose-dependent. At the histological level (Table 5), in the animals treated with the
dose 107 CFU/day, an improvement in the villus height/crypt depth ratio (VH/CD) was observed after the ingestion of the strain for 28 days. A higher VH/CD ratio is associated with a better intestinal capacity and better resistance to diarrhea at weaning [Dowarah et al., Livestock Science, 2017, 195, 74-79].Table 2. Growth performance results BW0 BW7 BW14 BW28 Hom_BW0 Hom_BW7 Hom_BW14 Hom_BW28 ADG0_7 ADG7_14 ADG0_14 ADG14_28 ADG0_28 T1 8.73 9.89 11.54 16.41 93.31 92.37 91.32 88.96 144.0 110.7 187.6 374.1 274.7 T2 8.74 9.84 11.51 16.32 92.81 91.72 90.98 88.56 137.4 110.2 184.3 370.6 270.7 T3 8.75 9.82 11.59 16.33 93.01 91.92 91.26 89.54 134.8 118.2 190.1 364.8 271.0 SEM 0.276 0.058 0.099 0.194 0.442 0.591 0.742 0.762 7.226 5.120 6.494 12.155 6.891 P-value 0.999 0.656 0.842 0.939 0.728 0.724 0.943 0.660 0.653 0.467 0.822 0.861 0.899 T1 : Treatment 109 CFU/day, T2:Treatment 107 CFU/day, T3: control, SEM: Standard error of the mean, BW#: body weight (g), # is the number of days after start of the study; Hom: Homogeneity; ADG#1_#2: Average Daily Gain (g), wherein #1 and #2 indicate the days after start of the study that are compared.Table 3. E. coli counts and blood cytokines levels. T1 (N=16) T2 (N=16) T3 (N=16) p-value W0 W4 KW p-value W0 W4 KW p-value W0 W4 KW p-value n Median (IQR) n Median (IQR) n Median (IQR) n Median (IQR) n Median (IQR) n Median (IQR) W0 W4 E. coli 1 6 1.00E+05 (4.38E+04, 6.63E+05) 16 3.75E+05 (8.88E+04, 1.18E+06) 0.509 16 3.25E+05 (1.00E+04, 1.13E+06) 1 6 2.00E+06 (6.25E+05, 4.29E+06) 0.022 16 3.03E+05 (7.88E+04, 4.25E+06) 16 3.00E+06 (7.88E+05, 9.25E+06) 0.025 0.522 0.006 IL-1β 2 51.67 (46.92, 56.43) 0 NA (NA, NA) --- 1 78.66 (78.66, 78.66) 2 5.76 (4.79, 6.72) 0.221 1 1.58 (1.58, 1.58) 0 NA (NA, NA) --- 0.259 --- IL-4 3 8.62 (6.49, 8.83) 5 2.3 (2.16, 2.30) 0.177 3 5.46 (4.04, 23.98) 1 2.21 (2.21, 2.21) 0.180 2 16.99 (9.65, 24.34) 3 4.42 (3.36, 8.85) 0.767 0.946 0.377 IL-6 1 209.93 (209.93, 209.93) 3 3.1 (2.26, 31.09) 0.180 1 49.3 (49.30, 49.30) 2 7.23 (4.53, 9.93) 0.221 0 NA (NA. NA) 3 10.42 (6.61. 12.05) --- 0.317 0.895 IL-8 1 5 60.27 (27.98, 281.98) 15 373.71 (231.69, 472.41) 0.001 14 171.35 (49.32, 282.92) 14 349.85 (272.39, 692.78) 0.002 14 152.31 (22.86, 314.97) 14 370.87 (335.12, 625.56) 0.007 0.763 0.955 IL-10 1 113.98 (113.98, 113.98) 1 153.26 (153.26, 153.26) --- 2 126.45 (88.85, 164.05) 0 NA (NA, NA) --- 0 NA (NA, NA) 0 NA (NA. NA) --- 1.000 --- IL-12p40 1 3 754.85 (463.21, 952.96) 13 1.080.18 (665.56, 1.927.42) 0.161 13 602.45 (422.07, 2.110.76) 14 1.076.93 (655.29, 1.785.77) 0.207 12 662.24 (469.99, 938.73) 15 1.050.11 (552.20, 1.396.81) 0.107 0.957 0.916 INFα 1 3 7.28 (5.41, 20.90) 9 3.14 (1.15, 7.01) 0.133 15 20.05 (5.59, 72.43) 11 1.75 (0.56, 5.85) 0.007 13 12.85 (4.70, 36.33) 12 2.74 (0.89, 9.40) 0.103 0.424 --- INFγ 1 53.42 (53.42, 53.42) 0 NA (NA, NA) --- 2 239 (127.45, 350.54) 0 NA (NA, NA) --- 0 NA (NA, NA) 0 NA (NA, NA) --- 1.000 --- TNFα 1 191.11 (191.11, 191.11) 0 NA (NA, NA) --- 1 434.04 (434.04, 434.04 0 NA (NA, NA) --- 0 NA (NA, NA) 0 NA (NA, NA) --- 0.317 0.778 T1: Treatment 109 CFU/day, T2: Treatment 107 CFU/day, T3: control, W0: initial week; W4: final week, KW: Kruskal-Wallis test, NA: not available. Table 4. Intestine anatomy results LENGTH (m) SI LI T1 14.612 3.000 T2 13.711 2.748 T3 13.360 2.519 SEM 0.296 0.107 P-value 0.034 0.029 T1: Treatment 109 CFU/day, T2:Treatment 107 CFU/day, T3: control, SI: Small intestine, LI: Large intestine, SEM: Standard error of the mean.Table 5. Intestine histology morphometry JEJUNUM VH CD VH:CD ratio IEL IEL/100 µm GC GC/100um MITOSES MITOSES/100 µm T1 616.7 209.8 3.105 16.98 2.81 11.25 3.54 0.573 0.260 T2 636.5 201.2 3.337 15.32 2.44 10.51 1.70 0.800 0.398 T3 558.3 218.3 2.670 16.44 2.92 11.75 2.10 0.756 0.348 SEM 35.520 8.836 0.158 0.918 0.185 0.430 1.090 0.152 0.066 P-value 0.280 0.411 0.027 0.390 0.152 0.133 0.416 0.496 0.291 ILEUM VH CD VH:CD ratio IEL IEL/100 µm GC GC/100um MITOSES MITOSES/100 µm T1 404.0 217.0 1.938 13.41 3.36 5.62 1.41 0.487 0.228 T2 377.2 173.0 2.477 14.96 4.20 5.15 1.40 0.490 0.283 T3 349.3 207.2 1.822 17.68 5.56 3.74 1.11 0.513 0.260 SEM 36.096 12.412 0.313 1.848 0.718 0.672 0.196 0.117 0.061 P-value 0.576 0.058 0.316 0.151 0.125 0.156 0.491 0.985 0.818 T1: Treatment 109 CFU/day, T2:Treatment 107 CFU/day, T3: control, VH: villus height, CD: crypt depth, IEL: intra-epithelial lymphocytes, GC: Goblet cells, SEM: Standard error of the mean - Feed samples were diluted 10-times in peptone water (Oxoid) and digested in a masticator. Serial 10-fold dilutions were prepared in peptone water and plated in MRScys agar plates (Oxoid). Plates were incubated at 37°C, in anaerobiosis, for 48h. After the incubation, CFU were counted and bacterial concentration per feed gram calculated considering the dilution in which colonies were counted.
- As for the feed samples, strain L. salivarius PS21603 has been recovered at the concentration that was estimated to comply with the doses of 107 and 109 CFU/day, so that the animals were correctly supplemented during the study period.
- The analysis of the sequencing of the fecal microbiome showed that the strain is extremely selective against E. coli. The administration of L. salivarius strain PS21603 at a dose of 109 CFU/day significantly reduced the concentration of E. coli in the intestine of piglets. This reduction is also appreciable in the group that received the dose of 107 CFU/day, although it is not statistically significant (Table 6).
- At the end of the study, the L. salivarius PS21603 strain was well tolerated by the piglets. Neither growth retarding nor inflammation was detected in treatment groups in comparison to control group. In addition, microbiological and anatomical differences were observed between animals treated with L. salivarius P21603 strain with respect to those that were not treated, demonstrating that the treatment does exert an effect on the intestinal microbiota of healthy piglets after weaning.
Table 6. Microbiome changes expressed in detection frequencies. T1 T2 T3 W0 W4 p-value ‡ W0 W4 p-value ‡ W0 W4 p-value ‡ Phylum Proteobacteria 0.107 0.051 0.087* 0.078 0.054 NS 0.079 0.058 NS Coriobacteriaceae 0.015 0.035 NS 0.016 0.038 0.036 0.023 0.017 NS Erysipelotrichaceae 0.019 0.025 NS 0.014 0.038 0.005 0.017 0.017 NS Coprobacillaceae 0.002 0.048 0.017 0.006 0.057 0.005 0.007 0.007 NS Flexibacteraceae 0.003 0.009 NS 0.004 0.008 NS 0.006 0.014 0.031 Family Streptococcaceae 0.005 0.002 0.041 0.002 0.002 NS 0.003 0.002 NS Turicibacteraceae 0.004 0.000 0.000 0.001 0.000 NS 0.001 0.000 NS Thermomonosporaceae 0.001 0.002 NS 0.001 0.001 NS 0.001 0.001 NS Geobacteraceae 0.000 0.001 0.009 0.000 0.001 0.000 0.000 0.000 NS Saprospiraceae 0.000 0.001 0.000 0.000 0.001 0.000 0.000 0.001 NS Catenibacterium 0.001 0.050 0.014 0.003 0.061 0.002 0.007 0.007 NS Escherichia 0.049 0.003 0.017 0.023 0.004 NS 0.025 0.012 NS Slackia 0.008 0.021 0.015 0.009 0.026 0.000 0.010 0.012 NS Genus Megasphaera 0.005 0.019 NS 0.001 0.011 NS 0.002 0.031 0.000 Streptococcus 0.006 0.002 0.049 0.002 0.002 NS 0.003 0.002 NS Turicibacter 0.004 0.000 0.000 0.001 0.000 0.000 0.001 0.000 0.000 Sarcina 0.003 0.000 0.008 0.001 0.000 NS 0.001 0.000 NS T1: Treatment 109 CFU/day, T2:Treatment 107 CFU/day, T3: control, W0: initial week; W4: final week, NS: non-significant. ‡p-value from HSD de Tukey test. * 90% signification level
Claims (15)
- A strain of Lactobacillus salivarius PS21603 or a variant thereof having at least 95% identity with this strain, wherein the variant strains are obtained by using the deposited strain as starter material, and wherein the variant strains retain or further improve the activity of the strain Lactobacillus salivarius PS21603.
- The strain as defined in claim 1, having at least 97% identity with the strain of Lactobacillus salivarius PS21603.
- The strain as defined in claim 2, wherein the strain is Lactobacillus salivarius PS21603.
- The strain as defined in any of claims 1 to 3, wherein the strain is alive.
- A composition comprising a strain as defined in any of claims 1 to 4.
- The composition according to claim 5, which further comprises a veterinary or pharmaceutically acceptable excipient.
- The composition according to claim 6, wherein the veterinary or pharmaceutically acceptable excipient is maltodextrin.
- The composition according to any of claims 5 to 7, which further comprises a foodstuff.
- The composition according to claim 8, wherein the foodstuff is an animal feed.
- A strain as defined in any of claims 1 to 4 or a composition as defined in any of claims 5 to 9, for use as a probiotic.
- A strain as defined in any of claims 1 to 4 or a composition as defined in any of claims 5 to 9, for use as a prevention and/or therapeutic agent.
- A strain as defined in any of claims 1 to 4 or a composition as defined in any of claims 5 to 9, for use in the prevention and/or treatment of diarrhea in a mammal.
- The strain or the composition for use according to claim 12 in the prevention and/or treatment of post-weaning diarrhea in a pig.
- A strain as defined in any of claims 1 to 4 or a composition as defined in any of claims 5 to 9, for use in improving performance of a mammal animal.
- The strain or the composition for use according to claim 14, wherein the animal is a pig.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19382407.5A EP3741218A1 (en) | 2019-05-21 | 2019-05-21 | Lactobacillus salivarus strain and its use in the prevention and treatment of post-weaning diarrhea in piglets |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19382407.5A EP3741218A1 (en) | 2019-05-21 | 2019-05-21 | Lactobacillus salivarus strain and its use in the prevention and treatment of post-weaning diarrhea in piglets |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3741218A1 true EP3741218A1 (en) | 2020-11-25 |
Family
ID=66685536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19382407.5A Pending EP3741218A1 (en) | 2019-05-21 | 2019-05-21 | Lactobacillus salivarus strain and its use in the prevention and treatment of post-weaning diarrhea in piglets |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP3741218A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113215063A (en) * | 2021-06-16 | 2021-08-06 | 中国药科大学 | Lactobacillus salivarius and application thereof |
CN115466699A (en) * | 2022-09-28 | 2022-12-13 | 成都大熊猫繁育研究基地 | Panda-derived lactobacillus salivarius and application thereof in treating or preventing inflammatory bowel disease |
CN116200313A (en) * | 2023-04-07 | 2023-06-02 | 西南科技大学 | Lactobacillus salivarius and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030063960A (en) * | 2002-01-24 | 2003-07-31 | 주식회사 프로바이오닉 | Acid tolerant probiotic Lactobacillus slivarius Probio-37 that can suppresses the growth of pathogenic microorganisms and TGE coronavirus |
KR101335455B1 (en) * | 2013-07-18 | 2013-12-02 | (주) 피엘바이오 | Novel Lactobacillus sp. strains and their use as probiotics |
-
2019
- 2019-05-21 EP EP19382407.5A patent/EP3741218A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030063960A (en) * | 2002-01-24 | 2003-07-31 | 주식회사 프로바이오닉 | Acid tolerant probiotic Lactobacillus slivarius Probio-37 that can suppresses the growth of pathogenic microorganisms and TGE coronavirus |
KR100585392B1 (en) * | 2002-01-24 | 2006-05-30 | 주식회사 프로바이오닉 | Acid tolerant probiotic Lactobacillus slivarius Probio-37 that can suppresses the growth of pathogenic microorganisms and TGE coronavirus |
KR101335455B1 (en) * | 2013-07-18 | 2013-12-02 | (주) 피엘바이오 | Novel Lactobacillus sp. strains and their use as probiotics |
Non-Patent Citations (35)
Title |
---|
ABEDE ET AL., EUROP. J. APPL. SCI., vol. 8, no. 5, 2016, pages 301 - 310 |
ARROYO ET AL., CLIN INFECT DIS, vol. 50, 2010, pages 1551 - 1558 |
BRYANKWAN, J ANTIMICROB CHEMOTHER, vol. 8, no. D, 1981, pages 1 - 8 |
CHARTERIS ET AL., J FOOD PROT, vol. 61, no. 12, 1998, pages 1636 - 1643 |
DANIELSENWIND, INT J FOOD MICROBIOL, vol. 82, no. 1, 2003, pages 1 - 11 |
DAVID H FRANCIS: "Enterotoxigenic Escherichia coli infection in pigs and its diagnosis", J SWINE HEALTH PROD, vol. 10, no. 4, 2002, pages 171 - 175, XP055638918, DOI: https://www.aasv.org/shap/issues/v10n4/v10n4p171.html * |
DENG ET AL., RES VET SCI, vol. 94, 2013, pages 62 - 68 |
DOWARAH ET AL., LIVESTOCK SCIENCE, vol. 195, 2017, pages 74 - 79 |
ELKINSMULLIS, APPL ENVIRON MICROBIOL, vol. 70, no. 12, 2004, pages 7200 - 7209 |
GHAREEB ET AL., POULT SCI, vol. 91, 2012, pages 1825 - 1832 |
GUIMONDE ET AL., FRONT MICROBIOL, vol. 4, 2013, pages 202 |
HARRIS ET AL., MICROB GENOM, vol. 3, 2017, pages e000115 |
HEIKKILASARIS, JAPPL MICROBIOL, vol. 95, 2003, pages 471 - 478 |
HUANG ET AL., ASIAN-AUST J ANIM SCI, vol. 17, no. 3, 2004, pages 401 - 409 |
JAIMEEHALAMI, APPL MICROBIOL BIOTECHNOL, vol. 100, no. 3, 2016, pages 1137 - 1151 |
JANADEB, APPL MICROBIOL BIOTECHNOL, vol. 70, 2006, pages 140 - 150 |
KANG ET AL., PATHOG DIS, vol. 75, no. 2, 2017 |
KLARE ET AL., JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 59, 2005, pages 900 - 912 |
KORHONEN ET AL., J APPL MICROBIOL, vol. 103, no. 6, 2007, pages 2496 - 2503 |
KULLEN ET AL., JOURNAL OF APPLIED MICROBIOLOGY, vol. 89, 2000, pages 511 - 518 |
MAPPLEY ET AL., APPL ENVIRON MICROBIOL, vol. 77, 2011, pages 5402 - 5411 |
O 'SHEA ET AL., GUT MICROBES, vol. 3, no. 5, 2012, pages 468 - 473 |
RAMIREZTOLMASKY, DRUG RESIST UPDAT, vol. 13, no. 6, 2010, pages 151 - 171 |
RICCI ET AL., EFSA JOURNAL, vol. 15, no. 3, 2017, pages 177 |
SAJEDINEJAD ET AL., PROBIOTICS ANTIMICROB PROTEINS, vol. 10, 2018, pages 218 - 227 |
SANUDO ET AL., ARCH ORAL BIOL, vol. 84, 2017, pages 58 - 63 |
SCHLESSINGER, CLIN MICROBIOL REV, vol. 1, 1988, pages 54 - 59, Retrieved from the Internet <URL:https://doi.org/10.1128/CMR.1.1.54> |
STEYGER, THE VOLTA REVIEW, vol. 105, no. 3, 2005, pages 299 - 324 |
TABER ET AL., MICROBIOL REV, vol. 51, no. 4, 1987, pages 439 - 457 |
TREVISI ET AL., ANIMAL, vol. 9, no. 9, 2011, pages 1354 - 1360 |
WU YUNPENG ET AL: "Protective effects ofLactobacillus plantarumon epithelial barrier disruption caused by enterotoxigenicEscherichia coliin intestinal porcine epithelial cells", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, ELSEVIER BV, AMSTERDAM, NL, vol. 172, 5 March 2016 (2016-03-05), pages 55 - 63, XP029481577, ISSN: 0165-2427, DOI: 10.1016/J.VETIMM.2016.03.005 * |
YAMAKAZI ET AL., BR POULT SCI, vol. 53, 2012, pages 183 - 189 |
YEO SOYOUNG ET AL: "Development of putative probiotics as feed additives: validation in a porcine-specific gastrointestinal tract model", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 100, no. 23, 15 September 2016 (2016-09-15), pages 10043 - 10054, XP036094403, ISSN: 0175-7598, [retrieved on 20160915], DOI: 10.1007/S00253-016-7812-1 * |
ZHANG ET AL., CURR MICROBIOL, vol. 62, 2011, pages 1623 - 1631 |
ZHOU ET AL., INT J FOOD MICROBIOL, vol. 98, no. 2, 2005, pages 211 - 217 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113215063A (en) * | 2021-06-16 | 2021-08-06 | 中国药科大学 | Lactobacillus salivarius and application thereof |
CN113215063B (en) * | 2021-06-16 | 2023-02-21 | 中国药科大学 | Lactobacillus salivarius and application thereof |
CN115466699A (en) * | 2022-09-28 | 2022-12-13 | 成都大熊猫繁育研究基地 | Panda-derived lactobacillus salivarius and application thereof in treating or preventing inflammatory bowel disease |
CN116200313A (en) * | 2023-04-07 | 2023-06-02 | 西南科技大学 | Lactobacillus salivarius and application thereof |
CN116200313B (en) * | 2023-04-07 | 2023-11-21 | 西南科技大学 | Lactobacillus salivarius and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11760970B2 (en) | Lactobacillus plantarum and composition comprising the same | |
Hayakawa et al. | Dietary administration of probiotics to sows and/or their neonates improves the reproductive performance, incidence of post‐weaning diarrhea and histopathological parameters in the intestine of weaned piglets | |
Cao et al. | Effects of a probiotic, Enterococcus faecium, on growth performance, intestinal morphology, immune response, and cecal microflora in broiler chickens challenged with Escherichia coli K88 | |
Oyetayo et al. | Safety and protective effect of Lactobacillus acidophilus and Lactobacillus casei used as probiotic agent in vivo | |
Guerra et al. | Production of four potentially probiotic lactic acid bacteria and their evaluation as feed additives for weaned piglets | |
De Lange et al. | Strategic use of feed ingredients and feed additives to stimulate gut health and development in young pigs | |
EP2162143B1 (en) | Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis | |
Kantas et al. | A feed additive containing Bacillus toyonensis (Toyocerin®) protects against enteric pathogens in postweaning piglets | |
Xu et al. | Micro-encapsulated essential oils and organic acids combination improves intestinal barrier function, inflammatory responses and microbiota of weaned piglets challenged with enterotoxigenic Escherichia coli F4 (K88+) | |
JP5411405B2 (en) | Antidiarrheal agent for livestock and poultry | |
EP3747989B1 (en) | Lactobacillus plantarum cjlp17 having antiviral and immunomodulatory efficacy and composition comprising same | |
EP3741218A1 (en) | Lactobacillus salivarus strain and its use in the prevention and treatment of post-weaning diarrhea in piglets | |
WO1993002558A1 (en) | Method and formulation for reducing microbial populations | |
Strompfová et al. | Lactobacilli and enterococci—potential probiotics for dogs | |
AU1365392A (en) | Feed additive and method | |
CN111032857B (en) | Composition comprising Lactobacillus plantarum CJLP475 strain and Lactobacillus plantarum CJLP243 strain and application thereof | |
US8673290B2 (en) | Sporulation-deficient B. texasporus cells and methods for efficient and cost-effective inactivation and use thereof | |
WO1999028441A1 (en) | Novel bacillus subtilis with antibacterial effects | |
Al-Sagan et al. | Effect of eubiotic administration to broiler's feed on intestinal morphology and microbiology under Clostridium perfringens challenge | |
F Farag et al. | The Effect Of Bacillus Subtilis On The Bacterial Content In Rabbits Caeci | |
KR20240043193A (en) | Novel Enterococcus lactis IDCC 2105 having anti-obesity activity and uses thereof | |
Tchórzewska | An in Vitro and in Vivo Assessment of Lactobacillus Plantarum and Lastulose as an Intervention Strategy Against S. Typhimurium in Pigs | |
Ariyadi | The effects of single lactic acid bacteria probiotic supplementation on intestinal mucosa profile and immune response in broilers | |
Kantas et al. | A feed additive containing Bacillus toyonensis in weaning piglets | |
Zhang et al. | Administration of Saccharomyces boulardii ma c-1701 improves feed conversion ratio, promotes antioxidant capacity, alleviates intestinal inflammation and modulates gut microbiota in weaned piglets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210525 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230522 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240610 |